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Abstract
Background:  High-dose radiotherapy is standard treatment for patients with brain cancer.
However, in preclinical research external beam radiotherapy is limited to heterotopic murine
models– high-dose radiotherapy to the murine head is fatal due to radiation toxicity. Therefore,
we developed a stereotactic brachytherapy mouse model for high-dose focal irradiation of
experimental intracerebral (orthotopic) brain tumors.
Methods: Twenty-one nude mice received a hollow guide-screw implanted in the skull. After
three weeks, 5 × 105 U251-NG2 human glioblastoma cells were injected. Five days later, a 2 mCi
iodine-125 brachytherapy seed was inserted through the guide-screw in 11 randomly selected
mice; 10 mice received a sham seed. Mice were euthanized when severe neurological or physical
symptoms occurred. The cumulative irradiation dose 5 mm below the active iodine-125 seeds was
23.0 Gy after 13 weeks (BEDtumor = 30.6 Gy).
Results: In the sham group, 9/10 animals (90%) showed signs of lethal tumor progression within 6
weeks. In the experimental group, 2/11 mice (18%) died of tumor progression within 13 weeks.
Acute side effects in terms of weight loss or neurological symptoms were not observed in the
irradiated animals.
Conclusion:  The intracerebral implantation of an iodine-125 brachytherapy seed through a
stereotactic guide-screw in the skull of mice with implanted brain tumors resulted in a significantly
prolonged survival, caused by high-dose irradiation of the brain tumor that is biologically
comparable to high-dose fractionated radiotherapy– without fatal irradiation toxicity. This is an
excellent mouse model for testing orthotopic brain tumor therapies in combination with radiation
therapy.
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Background
Postoperative radiotherapy is standard treatment for most
patients with malignant brain tumors, including gliomas,
malignant meningiomas, brain metastases, and medul-
loblastomas [1]. High doses of radiotherapy, i.e. 50–80
Gy or more given during 5–8 weeks, are required to con-
trol tumor growth. Despite these aggressive radiotherapy
regimens, the five-year survival of patients with a brain
tumor remains poor, ranging from a few percent for brain
metastases, 10% for glioblastoma multiforme [2], 50%
for low-grade glioma [3], 70% for childhood medullob-
lastoma [4], to 88% for meningioma [5]. Brachytherapy
with radioactive iodine-125 (125I) seeds, which is effective
against brain tumors, is used mostly for re-irradiation of
recurrent brain tumors [6-9].
Although radiotherapy has been proven to be effective in
prolonging survival and improving the quality-of-life of
brain tumor patients, further research is warranted to
increase its effectiveness. In glioma patients, success is
expected of combination therapy using radiotherapy and
either cytostatic drugs [10-12], molecular pathway modi-
fiers [13], or hyperthermia [14,15], although none of
these strategies has resulted in major improvements in
prognosis.
Experimental treatment requires pre-clinical animal mod-
els. Experimental radiotherapeutic studies are usually per-
formed with xenotransplantation of tumors in the hind
leg of immunocompromised mice (heterotopic implanta-
tion) instead of implantation in the brain (orthotopic
implantation) because high-dose external beam radio-
therapy in the latter case is fatal for small animals [16-18].
The minimal reliable field size for external irradiation is
approximately 1 cm2 with the use of appropriate shield-
ing. This is feasible for low dose treatment of e.g. rat
brains, which are much larger than murine brains [19].
Due to the dimensions of smaller rodents such as mice, it
is not possible to deliver a high external beam radiation
dose to tumors in the brain without irradiating surround-
ing tissues such as the normal brain and esophagus.
In the present study, we have investigated whether fatal
irradiation toxicity can be prevented by implantation of
an 125I brachytherapy seed to enable local high-dose irra-
diation of an orthotopic xenotransplanted glioblastoma
in the mouse brain.
Methods
Implantation of a hollow guide-screw in the mouse skull 
(day -26)
Athymic Nude-nu female mice (Harlan, Horst, The Neth-
erlands), 4–6 weeks of age, were kept in four groups of six.
Prior to cancer cell injection on day -26 (day 0 is the start
of therapy) a hollow guide-screw was implanted in the
skull of the mouse [20]. Before surgery, each mouse was
anesthetized by injection of FFM-mix (fentanyl citrate, flu-
anisone, midazolam, 0.1 ml per 10 gram body weight).
The mice were then placed in a holder to fix the head. The
skin was disinfected with iodine (1% iodine, 70% alco-
hol). A small incision was made and a drop of 3% lido-
caine was put on the skull surface. A sterilized hand drill
(9905 Dremel™, Breda, The Netherlands) was used to drill
a burr-hole through the skull, in the right frontolateral
position, to hold the screw (Figure 1). The skin was closed
with three stitches. One hundred microliters phosphate-
buffered saline were injected intraperitoneally for optimal
recovery by preventing dehydration.
Culture of glioblastoma cells
The glioblastoma cell line U251-NG2, a transfected
human glioblastoma cell line with an overexpression of
NG2 (provided by dr. Chekenya and prof. Bjerkvig, Uni-
versity of Bergen, Norway), was used for orthotopic
xenotransplantation in the nude mouse brain. We
selected the U251-NG2 cell line to investigate combina-
tion therapy consisting of radiotherapy and antiang-
iogenic drugs in future experiments. The glial precursor
proteoglycan, neuron glia 2 (NG2), promotes angiogen-
esis-dependent tumor growth in the brain [21,22].
The cells were grown in Dulbecco's Modified Eagle's
Medium (DMEM) with the addition of 10% heat inacti-
vated newborn calf serum, four times the prescribed
amount of amino acids, 800 μg/ml neomycin and 100 IU/
ml penicillin/streptomycin (Gibco, Paisley, UK) [22].
Neomycin was added to select for neomycin-resistant
Stereotactic screw Figure 1
Stereotactic screw. The in-house developed hollow plastic 
stereotactic screw for implantation in the mouse skull. The 
inner diameter was 0.9 mm to tightly fit an 125I brachytherapy 
seed. Dimensions are given in mm. M3: metric screw thread 
3.Radiation Oncology 2007, 2:38 http://www.ro-journal.com/content/2/1/38
Page 3 of 7
(page number not for citation purposes)
clones that overexpress NG2. Cells were grown in culture
flasks (Costar, Corning, NY, USA) in a humidified incuba-
tor at 37°C, in air mixed with 10% CO2. Two hours before
cell transplantation, cells were harvested from the flasks
by adding 2 ml trypsin. After washing, suspensions of 5 ×
107 cancer cells in 300 μl PBS were prepared and kept on
ice.
Administration of U251-NG2 cells (day -5)
Three weeks after implantation of the screw (day -5), each
mouse was anesthetized with 0.07 ml FFM-mix per 10
gram body weight intraperitoneally, and fixed in the
holder. The skin was disinfected, the previous incision
scar was reopened, and the guide-screw was exposed.
Through the central canal a microsyringe (pt.style #3;
Hamilton, Bonaduz, Switzerland) was inserted. A blocker
or 'arret' was attached to the syringe to be able to inject
cancer cell suspensions precisely 2 mm below the screw in
the right frontolateral brain (Figure 2). A suspension of 5
× 105 cancer cells in 3 μl PBS was injected slowly during 1
minute. The syringe was removed and the skin closed; the
mouse recovered after injection of 0.1 ml PBS intraperito-
neally.
Iodine-125 brachytherapy seed implant (day 0)
Five days after cancer cell injection, each mouse was anes-
thetized again, the skin reopened and the guide-screw
exposed. A 2 mCi 125I seed (model 6711; Medi-Physics,
Amersham, Arlington Heights, IL, USA) or an inactive
sham seed was inserted through the hole in the screw (Fig-
ures 2 and 3). Eleven mice received an experimental seed;
ten mice received a sham seed; three mice died before seed
implantation.
Follow-up and euthanasia (day 1–91)
All mice were kept in a specific pathogen-free environ-
ment with optimal feeding, temperature and hygienic
conditions and ample space, according to stringent exper-
imental animal facility regulations. Mice were observed
and weighed daily. Euthanasia was performed in case of
extreme weight loss (more than 20 percent of body weight
at the start of the experiment), the development of a
domehead, occurrence of rotational behavior or other
severe neurological signs, or when there were signs of
dehydration. Euthanasia was performed on all surviving
animals after 13 weeks by introducing CO2 into a sealed
cage. After death, the skull was opened and the brains
removed for histological analysis. All mouse experiments
were approved, monitored and reviewed by the university
committee for animal experiments.
After hematoxylin-eosin staining, histological analysis
was performed on every twentieth 8 μm section across the
entire formalin-fixed brain. Magnetic resonance imaging
with gadolinium enhancement was performed in a 1.5 T
MRI scanner (Signa LX, General Electric Co, Waukesha,
Mouse MRI Figure 3
Mouse MRI. Magnetic resonance image (1.5 Tesla) of the 
head of a U251-NG2 glioblastoma-bearing mouse (sagittal 
view) with gadolinium contrast enhancement 61 days after 
cancer cell injection. No seed was inserted in this case.
Sagittal view Figure 2
Sagittal view. Schematic sagittal view through the head of 
an intracerebral brain tumor-bearing mouse with implanted 
stereotactic screw containing an 125I brachytherapy seed. 
Cumulative radiation dose during 13 weeks for a 2 mCi 125I 
brachytherapy seed at four distances from the seed: (a) 2.5 
mm below ('tumor dose' 52.1 Gy [integrated biological effec-
tive dose (BED) 91.2 Gy]), (b) 5 mm below ('minimal tumor 
dose' 23.0 Gy [integrated BED 30.6 Gy]), (c) 10 mm below 
('pharynx dose' 7.8 Gy [integrated BED 8.7 Gy]) and (d) 5 
mm central lateral (138.3 Gy [integrated BED 414.2 Gy]). T, 
tumor; B, brain; GS, subcutaneous plastic guide-screw 
through the skull.Radiation Oncology 2007, 2:38 http://www.ro-journal.com/content/2/1/38
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USA). Two tumor-bearing mice without implanted seeds
were scanned 61 days after cancer cell injection. Mouse
survival was calculated by the Kaplan & Meier method and
compared by the log rank-test in SPSS©.
Results
Animal survival
Figure 4 shows the survival curves for 11 glioblastoma-
bearing mice implanted with a radioactive 125I seed and
10 glioblastoma-bearing mice with a sham seed. In the
sham seed group, 9/10 (90%) died from tumor progres-
sion within 6 weeks. Only 2/11 (18%) mice with the 125I
seed died from tumor progression within 13 weeks of seed
implantation. The median survival of mice implanted
with sham seeds was 4.6 weeks versus more than 13 weeks
for the mice implanted with radioactive seeds. The differ-
ence between the groups was highly significant (p <
0.0007). Similar results were observed in a second experi-
ment (data not shown).
Histological analysis
In the sham-treated mice, all 9 mice that died within 6
weeks showed intracranial glioblastoma (Figure 5a). The
only long-surviving sham seed-implanted mouse, which
was euthanized after 13 weeks, did not show signs of a
tumor (Figure 5b). Of the mice implanted with radioac-
tive seeds, both mice that were sacrificed before the end of
the study (after 2.6 and 8.6 weeks) showed vital tumor tis-
sue (Figure 5c). The nine long-surviving irradiated mice
showed either histological evidence of a few vital glioblas-
toma cells (n = 3; 33%) or no histological evidence of vital
tumor tissue but of brain trauma or a hypovascular brain
(Figure 5d).
Discussion
Our present study describes for the first time a mouse
model for high-dose radiotherapy of orthotopic brain
tumors. Irradiation of tumors was performed using a
guide-screw with a 2 mCi 125I brachytherapy seed. Irradi-
ation led to a significantly improved survival and higher
tumor control probability in U251-NG2 glioblastoma-
bearing nude mice. This mouse model may serve as an
experimental animal model to study the effects of combi-
nation therapy consisting of local high-dose irradiation
HE-stained sections Figure 5
HE-stained sections. Hematoxylin-eosin stained sections 
of mouse brain. (a) Section of an non-irradiated mouse brain 
with a large vital glioblastoma (T) that died 4.6 weeks after 
sham seed implantation. Normal brain tissue (B). (b) Section 
of the brain of the only long-surviving mouse in the group 
that was implanted with a sham seed. The mouse, euthanized 
91 days after implantation, showed no vital tumor. (c) Sec-
tion of the brain of an irradiated mouse that died from tumor 
progression 18 days after implantation of the 125I brachyther-
apy seed. Diffuse infiltration of cells (T) is present in the 
brain. (d) Section of the brain of an irradiated mouse eutha-
nized at 13 weeks after implantation of a 125I brachytherapy 
seed showing regions of mechanical trauma (D), hypovascu-
lar brain tissue next to normal brain (B), but no vital tumor.
Survival curves Figure 4
Survival curves. Survival curves for U251-NG2 glioblast-
oma-bearing mice treated with a stereotactically implanted 
125I brachytherapy seed (intermitted line) or a sham seed 
(uninterrupted line).Radiation Oncology 2007, 2:38 http://www.ro-journal.com/content/2/1/38
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and chemical compounds that may have an additional
therapeutic effect, such as new radio-sensitizing and anti-
angiogenic compounds.
The major advantage of this brachytherapy model com-
pared to external beam (orthovoltage) irradiation is that a
high radiation dose can be delivered to the murine ortho-
topic brain tumor without causing fatal toxicity to the nor-
mal brain and pharynx, as observed when comparable
doses of external beam irradiation are delivered. Apart
from a lower applicable radiation dose, external beam
irradiation is more labor-intensive because of the multiple
fractions of anesthetized treatment and is only applicable
to much larger rodents such as rats [19].
A few points of consideration about the model include the
steep dose and dose-rate-gradient around the 125I seed, the
relatively fast 125I radioactive decay (half-life of 59.4 days)
and the subsequent radiobiological uncertainties. How-
ever, similar or worse dosimetric problems are encoun-
tered when very small external photon beam fields are
used.
Dosimetric studies have shown that the measured dose
rates and the anisotropically 'apple' shaped dose rate dis-
tribution of a single seed vary within the measurement
error from the seed specifications provided by the manu-
facturer [23]. The steep dose-rate gradient around the seed
implanted in or adjacent to the tumor provides a high
dose rate and cumulative tumor dose close to the seed,
and thus to the tumor but a relatively low dose rate and
cumulative dose farther away from the seed and thus in
normal brain tissue. For example, for the 2 mCi 125I brach-
ytherapy seed the cumulative radiation dose is 138 Gy
after 13 weeks at 5 mm central lateral. At 5 mm below the
seed, where we defined the 'minimal tumor dose', the ini-
tial dose rate is 1.7 cGy/hr and the cumulative dose is 23.0
Gy after 13 weeks.
The BED of permanent seed implants is a point of ongo-
ing discussion [24]. The main concern is the uncertainty
about the biological significance of the residual source
activity after 1.5 source decay half-times of 125I (half-time
= 59.4 days) [25]. For both ethical and evaluation pur-
poses, we terminated our study at 13 weeks (91 days) after
implant of a 2 mCi 125I source. After this relatively short
period, we consider the BED approximations as proposed
by Dale and Jones [24] to be safe for low-dose rate perma-
nent implants removed after 90 days (see appendix for
calculation details). These calculations yield a BEDtumor
2.5 mm distal of the seed of 91.2 Gy, equivalent to a con-
ventional external beam radiotherapy dose of 76 Gy in
200 cGy daily fractions, which is more than clinically fea-
sible.
Although dose-rate effects are of major importance for
dose rates of 40 cGy/hr and higher, which is the range of
clinical dose rates, this is probably of less importance for
the permanent 125I implant (1–5 cGy/hr) [24]. During the
91 days of implantation of the 2 mCi source, the dose rate
5 mm below the source decays from 1.7 cGy/hr to 0.6
cGy/hr.
It is not clear whether these biological models can be
extrapolated to even lower dose rates after 2–3 decay half-
times for seeds with a lower initial activity, such as the 0.5
mCi sources that we use clinically for prostate cancer
implants [26], or in tumors with a very high doubling
time. This is not necessarily a disadvantage of our mouse
brachytherapy model; on the contrary, the model allows
in vivo study of these uncertainties of clinical brachyther-
apy.
Conclusion
Guide-screw implanted 125I brachytherapy seeds can be
used for experimental clinically significant irradiation of
an orthotopic glioblastoma implanted in the nude mouse
brain. The method is feasible, gives a high tumor control
probability and an improved survival rate of the U251-
NG2 glioblastoma-bearing mouse, without fatal irradia-
tion toxicity.
The major concern of the model is the steep dose-rate gra-
dient around the 125I seed with a correspondingly high
dose inhomogeneity in the tumor. Because of the very
high tumor control rate obtained in this model with little
margin for any gain from additive experimental drugs, we
recommend to use weaker 125I sources (1 mCi) for future
studies.
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Appendix
Calculation of the Biological Equivalence Dose (BED)
of permanent iodine-125 implants (according to Dale &
Jones, 1998):
According to the linear-quadratic model the biological
effective dose (BED) of fractionated external beam radio-
therapy can be given as:
where n = number of daily fractions, d = fraction dose (in
Gray), and the α/β ratio is the parameter for cellular sur-
vival. It is reasonable to assume an α/β-ratio of 3 Gy2 for
BED n d
d
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+ () α
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normal tissue and 10 Gy2 for rapidly proliferative tissue,
such as tumor and squamous cell epithelium.
For a permanent implant delivering an initial dose rate Ro,
and involving a nuclide with decay constant λ, DNA-
recovery constant μ, and cell-survival characteristics α/β,
BED is given as:
The mono-exponential recovery constant μ is related to
the repair half-life T1/2 by:
Average repair-half-lives for mammalian tissues are usu-
ally 0.5–3 h, with increasing evidence that tumor recovery
half-lives are probably shorter than those for late reacting
normal tissues. Assuming a tumor recovery half-life T1/2 =
1.5 h, than μ = 0.462 per hour.
The radioactive source decay constant λ is related to the
decay half-life T1/2 by:
The decay half-life T1/2 of iodine-125 is 59.4 days = 1425.6
hours. The decay constant is 0.000486 per hour.
For a non-permanent implant with a decaying source,
removed after time T:
where:
C = 1 - e-λT
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